搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按相关度排序
按时间排序
The Pharma Letter
6 小时
Roivant Phase II miss for namilumab
Roivant Sciences portfolio company Kinevant Sciences today revealed its Phase II study failed to show treatment benefit in ...
The Pharma Letter
7 小时
Atom and CMS to offer new drug for gout in China
Atom Therapeutics partners with China Medical System to commercialize lingdolinurad for gout and hyperuricemia in China, Hong ...
The Pharma Letter
7 小时
Sanofi punts 1 billion euros on new insulin production base in China
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing ...
The Pharma Letter
7 小时
COUR Pharma inks near billion dollar deal with Genentech
US privately-held biotech COUR Pharmaceuticals has entered into a strategic collaboration and licensing agreement with Roche ...
The Pharma Letter
6 小时
Takeda strengthens in oncology with Keros deal
Japanese pharma major Takeda has agreed an exclusive licensing agreement with US pharma Keros Therapeutics (Nasdaq: KROS) to ...
The Pharma Letter
6 小时
Conditional Chinese nod for cancer combination
China's National Medical Products Administration (NMPA) has granted conditional approval for a combination therapy of Elunate ...
The Pharma Letter
8 小时
Novartis deal and $250 million set Olema on the way
US biopharma Olema Pharmaceuticals has announced a clinical trial collaboration and supply agreement with Swiss pharma giant ...
The Pharma Letter
9 小时
Eckhard Niemeier to head up business at Nouscom
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized neoantigen cancer immunotherapies ...
The Pharma Letter
9 小时
TCR immunotherapy licensing deals in Europe outpace USA
Licensing agreement deal value for innovative T-cell receptor (TCR) immunotherapy drugs surged in 2024, with European ...
The Pharma Letter
10 小时
Senti Biosciences reports early success in AML trial
Senti Biosciences reports promising Phase I results for SENTI-202 in acute myeloid leukemia, with two of three patients ...
The Pharma Letter
10 小时
Efficacy of Vyepti highlighted by new clinical trial
New results from the RESOLUTION trial demonstrate the efficacy of Vyepti (eptinezumab) on top of patient education for ...
The Pharma Letter
11 小时
Bausch Health names new CMO and head of R&D
Bausch Health has appointed Dr Jonathan Sadeh as executive vice president, chief medical officer and head of R&D.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈